Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $11.56 Average PT from Analysts

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) have received a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.56.

A number of analysts have recently weighed in on the stock. Craig Hallum assumed coverage on shares of Maravai LifeSciences in a research note on Wednesday, April 10th. They issued a “buy” rating and a $15.00 price objective on the stock. Royal Bank of Canada increased their price objective on shares of Maravai LifeSciences from $12.00 to $14.00 and gave the stock an “outperform” rating in a research note on Friday, February 23rd. Finally, Stifel Nicolaus cut their price objective on shares of Maravai LifeSciences from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, February 23rd.

Maravai LifeSciences Trading Down 1.0 %

NASDAQ:MRVI opened at $8.87 on Monday. The company has a quick ratio of 7.41, a current ratio of 8.00 and a debt-to-equity ratio of 0.70. Maravai LifeSciences has a 52 week low of $4.52 and a 52 week high of $16.62. The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -9.73 and a beta of 0.03. The firm has a 50 day moving average of $8.07 and a 200 day moving average of $6.72.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Maravai LifeSciences had a negative net margin of 41.19% and a negative return on equity of 1.31%. The company had revenue of $74.14 million for the quarter, compared to analyst estimates of $62.99 million. As a group, sell-side analysts anticipate that Maravai LifeSciences will post -0.15 earnings per share for the current fiscal year.

Institutional Trading of Maravai LifeSciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its position in Maravai LifeSciences by 96.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 3,391 shares of the company’s stock valued at $34,000 after buying an additional 1,662 shares during the period. Signaturefd LLC grew its position in Maravai LifeSciences by 99.9% during the third quarter. Signaturefd LLC now owns 3,364 shares of the company’s stock valued at $34,000 after buying an additional 1,681 shares during the period. Wellington Management Group LLP lifted its holdings in Maravai LifeSciences by 2.6% during the third quarter. Wellington Management Group LLP now owns 70,658 shares of the company’s stock valued at $707,000 after purchasing an additional 1,779 shares in the last quarter. QRG Capital Management Inc. lifted its holdings in Maravai LifeSciences by 11.7% during the first quarter. QRG Capital Management Inc. now owns 17,143 shares of the company’s stock valued at $149,000 after purchasing an additional 1,796 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Maravai LifeSciences by 1.1% during the third quarter. Swiss National Bank now owns 246,500 shares of the company’s stock valued at $2,465,000 after purchasing an additional 2,600 shares in the last quarter. Institutional investors and hedge funds own 50.25% of the company’s stock.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.